Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)
China · Delayed Price · Currency is CNY 12.82
+0.01 (0.08%)
Feb 27, 2026, 3:04 PM CST
SHE:301211 Revenue
Hubei Biocause Heilen Pharmaceutical had revenue of 84.13M CNY in the quarter ending September 30, 2025, a decrease of -8.68%. This brings the company's revenue in the last twelve months to 430.77M, down -5.24% year-over-year. In the year 2024, Hubei Biocause Heilen Pharmaceutical had annual revenue of 445.86M, down -32.75%.
Revenue (ttm)
430.77M
Revenue Growth
-5.24%
P/S Ratio
12.43
Revenue / Employee
436.44K
Employees
987
Market Cap
5.35B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 445.86M | -217.16M | -32.75% |
| Dec 31, 2023 | 663.03M | 148.11M | 28.76% |
| Jan 1, 2023 | 514.91M | -25.71M | -4.76% |
| Jan 1, 2022 | 540.62M | -52.30M | -8.82% |
| Dec 31, 2020 | 592.92M | -67.09M | -10.17% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jianmin Pharmaceutical Group | 3.18B |
| Luoxin Pharmaceuticals Group Stock | 2.49B |
| Fuan Pharmaceutical (Group) | 1.71B |
| Hunan Fangsheng Pharmaceutical | 1.68B |
| Tianjin Lisheng Pharmaceutical | 1.32B |
| Bide Pharmatech | 1.27B |
| Zhuhai Rundu Pharmaceutical | 1.19B |
| Nanjing Hicin Pharmaceutical | 615.39M |